# Nicola Gökbuget

Source: https://onco.cc/people/nicola-gokbuget/  
OnCo record `nicola-gokbuget` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leads the German GMALL group and showed blinatumomab clears residual leukaemia in adults with ALL.

## Summary

Nicola Gökbuget leads the German Multicenter Study Group for Adult ALL (GMALL), whose trials defined risk-adapted therapy and MRD-guided treatment in adult ALL, and was principal investigator of the BLAST trial showing blinatumomab converts most MRD-positive patients to MRD-negative with improved survival, the basis for its MRD indication. She co-authored the European guidelines on adult ALL.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: all; mrd; cooperative-group
- Role: Head of the GMALL Study Group; Professor of Medicine, University Hospital Frankfurt
- Specialisms: Adult acute lymphoblastic leukaemia; Measurable residual disease; Cooperative-group trials; Immunotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Gokbuget%20N%5BAuthor%5D%20acute%20lymphoblastic%20leukemia

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/)
- institutions: [University Cancer Center Frankfurt (UCT)](https://onco.cc/institutions/uct-frankfurt/)
- key papers: [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/nicola-gokbuget.json